Open consultation on ICH E6 (R3) Annex 2
EMA has opened the public consultation on the draft Annex 2 of ICH E6(R3), following its adoption by EMA’s Committee for Medicinal Products for Human Use (CHMP). As part of the ICH E6 suite, this document addresses Good Clinical Practice (GCP), an international...
Key Takeaways from the CDDF Webinar on Perspectives on the new EU Health Technology Assessment HTA Regulation 2021/2282 (28 September 2023)
The Cancer Drug Development Forum (CDDF) held a live webinar on “Perspectives on the new EU Health Technology Assessment HTA Regulation 2021/2282 “ on Thursday 28 September 2023. In this webinar, Marcus Guardian and Julie Spony provided an overview of the topic...
Executive Summary of the Workshop on “Innovative Oncology Trial Designs” (September 2023, Amsterdam)
The Cancer Drug Development Forum (CDDF) has published its executive summary of the workshop on “Innovative Oncology Trial Designs.” The multi-stakeholder workshop took place on 18 – 19 September 2023 in Amsterdam, NL. The gathering brought together the...